

Lung Cancer

NATURAL HISTORY,
PROGNOSIS, AND THERAPY

EDITED BY

Lucien Israel, M.D.

A. Philippe Chahinian, M.D.

LUNG CANCER

Natural History, Prognosis, and Therapy

EDITED BY

Lucien Israel, M.D.

Centre Hospitalier
Universitaire Lariboisière
Paris, France

A. Philippe Chahinian, M.D.

Department of Neoplastic Diseases
Mt. Sinai School of Medicine
of The City University of New York
New York, New York

内部交流



ACADEMIC PRESS New York San Francisco London 1976

A Subsidiary of Harcourt Brace Jovanovich, Publishers

COPYRIGHT © 1976, BY ACADEMIC PRESS, INC.
ALL RIGHTS RESERVED.

NO PART OF THIS PUBLICATION MAY BE REPRODUCED OR
TRANSMITTED IN ANY FORM OR BY ANY MEANS, ELECTRONIC
OR MECHANICAL, INCLUDING PHOTOCOPY, RECORDING, OR ANY
INFORMATION STORAGE AND RETRIEVAL SYSTEM, WITHOUT
PERMISSION IN WRITING FROM THE PUBLISHER.

ACADEMIC PRESS, INC.
111 Fifth Avenue, New York, New York 10003

United Kingdom Edition published by
ACADEMIC PRESS, INC. (LONDON) LTD.
24/28 Oval Road, London NW1

Library of Congress Cataloging in Publication Data

Main entry under title:

Lung cancer : natural history, prognosis, and therapy.

Includes bibliographical references.

| | | |
|-----------------------------|--------------------|-----------------|
| 1. Lungs—Cancer. | I. Israel, Lucien. | Lung neoplasms. |
| II. Chahinian, A. Philippe. | [DNLM: 1. | |
| WF658 L963] | | |
| RC280.L8L78 | 616.9'94'24 | 75-30468 |
| ISBN 0-12-375050-4 | | |

PRINTED IN THE UNITED STATES OF AMERICA

List of Contributors

Numbers in parentheses indicate the pages on which the author's contributions begin.

A. Philippe Chahinian, M.D. (1, 63, 95, 151), Department of Neoplastic Diseases, Mt. Sinai School of Medicine of the City University of New York, New York, New York

Jacques Chrétien, M.D. (1), Respiratory Diseases, Hospital Intercommunal, Creteil, France

Elias G. Elias, M.D. (259),* Department of General Surgery, Roswell Park Memorial Institute, Buffalo, New York

Paul Lo Gerfo, M.D. (81), Department of Surgery, Columbia University College of Physicians and Surgeons, New York, New York

Lucien Israel, M.D. (63, 95, 141, 199, 273, 281, 285, 295, 301), Centre Hospitalier Universitaire Lariboisière, Paris, France

Bowen Keller, M.D. (159), Division of Radiation Oncology, Strong Memorial Hospital, Rochester, New York

Mary J. Matthews, M.D. (23), National Cancer Institute, Veterans Administration Medical Oncology Service, Washington, D.C., and George Washington University School of Medicine, Washington, D.C.

Olivier Monod, M.D. (241), Department of Thoracic Surgery, Centre Chirurgical du Val d'Or, Saint Cloud, France

Clifton F. Mountain, M.D. (107), Section of Thoracic Surgery, The University of Texas System Cancer Center, M. D. Anderson Hospital and Tumor Institute, Houston, Texas

Carlos A. Perez, M.D. (159), Division of Radiation Oncology, Washington University School of Medicine, St. Louis, Missouri

* Present address: Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland.

Preface

Lung cancer is one of the leading causes of death from malignant disease, and its incidence is increasing dangerously throughout the world. Cytotoxic agents and combined strategies, which have already enabled appreciable progress against some solid tumors such as breast cancer and ovarian cancer, have not, unfortunately, produced the same results against lung cancer. Far from being discouraging, this situation presents a challenge which should encourage greater effort in the analysis and refinement of existing concepts.

I have had occasion to meet fellow workers who are diligently engaged in achieving this goal. I asked them to contribute to this monograph which aims to provide an account of the knowledge acquired by several specialists through extensive personal experience; draw attention to methodologic progress, conceptual debates, and controversial points resulting from this experience; and encourage criticism, cooperation, and further investigation by other teams working in this field.

I have chosen to present papers from reknowned specialists in their fields in order to provide readers with recent, well-established data. My contributions are concerned with problems, speculations, and criticisms of current therapeutic strategies.

Due to the present frequency and widespread extension of this disease in all the advanced countries, this book should be of interest not only to specialists of respiratory diseases, but also to oncologists, surgeons, radiotherapists, immunologists, and internists. Only their combined efforts and interest can improve the prognosis of lung cancer.

I would like to extend my sincere thanks to all the authors who have contributed to this work with preciseness and independence of thought. I would like also to thank Dr. P. Chahinian whose help in editing this work was invaluable. We are indebted to Dr. R. Edelstein and Dr. M. L.

Slankard for reviewing our manuscripts. Finally, I would like to gratefully acknowledge the cordial and efficient assistance of the staff of Academic Press.

LUCIEN ISRAEL

Preface

Lung cancer is one of the leading causes of death from malignant disease, and its incidence is increasing throughout the world. Genetic agents and combined strategies which have already enabled appreciable progress against solid tumors such as breast cancer and ovarian cancer have not, unfortunately, produced the same results against lung cancer. But, this being the situation, this situation presents a challenge which should be met by the scientific and clinical communities in the development of new therapeutic approaches.

I have had occasion to meet fellow workers who are deeply engaged in solving this problem, and I feel that a contribution to this important field is due. It is my aim to present the current state of knowledge, acquired by genetic, epidemiologic, clinical, and experimental approaches, and to discuss the progress, conceptual, technical, and organizational problems resulting from this effort, and encourage further cooperation and further investigation by other teams working in this field.

I have chosen to present papers from renowned specialists in their fields in order to provide readers with recent well-established data. My contributions are concerned with genetic, epidemiologic, and clinical aspects of lung cancer.

The genetic, epidemiologic, and clinical aspects of lung cancer are of the utmost importance, but they should be of interest not only to specialists of respiratory diseases but also to oncologists, surgeons, radiotherapists, immunologists, and hematologists. Only their combined efforts and interest can improve the prognosis of lung cancer.

I would like to extend my sincere thanks to all the authors who have contributed to this work with precious and independent thoughts. I would like also to thank Dr. P. Chabot whose help in editing this book was invaluable. We are indebted to Dr. B. Chabot and Dr. M. J.

Contents

| | |
|--------------------------------|--|
| LIST OF CONTRIBUTORS | |
| PREFACE | |

Chapter 1 Present Incidence of Lung Cancer: Epidemiologic Data and Etiologic Factors

A. Philippe Chahinian and Jacques Chrétien

| | |
|----------------------------------|----|
| I. Present Incidence | 2 |
| II. Epidemiologic Data | 3 |
| III. Etiologic Factors | 5 |
| IV. Conclusion | 17 |
| References | 17 |

Chapter 2 Problems in Morphology and Behavior of Bronchopulmonary Malignant Disease

Mary J. Matthews

| | |
|---|----|
| I. Introduction | 23 |
| II. Embryology | 25 |
| III. Histogenesis | 27 |
| IV. Pathogenesis | 28 |
| V. Morphology | 30 |
| VI. Behavior of Lung Tumors and Related Problems | 47 |
| VII. Problems in Cytodiagnosis of Pulmonary Malignancies | 58 |
| VIII. Summary | 60 |
| References | 60 |

Chapter 3 Rates and Patterns of Growth of Lung Cancer

A. Philippe Chahinian and Lucien Israel

| | |
|--|----|
| I. The Exponential Model in Man | 64 |
| II. Analysis of DT | 66 |
| III. Is the DT Constant? | 68 |
| IV. Personal Data | 70 |
| V. Practical Consequences and Natural History of Solid Tumors | 71 |
| VI. Appendix: Measurement of Doubling Time | 73 |
| References | 76 |

Chapter 4 Tumor Antigens Associated with Lung Cancer

Paul Lo Gerfo

| | |
|---|----|
| I. Chemically or Physically Induced Tumor Antigens | 82 |
| II. Viral-Induced Tumor Antigens | 83 |
| III. Fetal Antigens | 85 |
| IV. Carcinoembryonic Antigen (CEA) | 86 |
| V. Gamma Fetal Protein (GFP) | 90 |
| VI. Regan Isoenzyme Alkaline Phosphatase (RI) | 91 |
| VII. Other Fetal Antigens Associated with Lung Carcinoma | 91 |
| References | 91 |

Chapter 5 Prognostic Value of Doubling Time and Related Factors in Lung Cancer

A. Philippe Chahinian and Lucien Israel

| | |
|--|-----|
| I. <i>DT</i> and Postoperative Survival | 95 |
| II. Correlation between <i>DT</i> and Various Parameters | 96 |
| III. <i>DT</i> and Other Parameters | 103 |
| IV. Conclusion | 104 |
| References | 104 |

Chapter 6 The Relationship of Prognosis to Morphology and the Anatomic Extent of Disease: Studies of a New Clinical Staging System

Clifton F. Mountain

| | |
|---|-----|
| I. General Considerations in Staging | 108 |
| II. The Classifications of Neoplastic Disease Extent | 109 |
| III. The New TNM System for Classifying Lung Cancer | 110 |
| IV. Stage Grouping of TNM Combinations | 116 |
| V. Survival Patterns of Anatomic TNM Subsets | 118 |
| VI. The Effect of Morphology on Anatomic Survival Patterns | 121 |
| VII. Other Factors Affecting Survival Patterns | 130 |
| VIII. Flexibility of the TNM System for Specialized Use | 132 |
| IX. Conclusions | 137 |
| References | 139 |

Chapter 7 Nonspecific Immunological Alterations in Patients with Lung Cancer

Lucien Israel

| | |
|--|-----|
| I. Pretherapeutic Immune Status in Advanced Lung Cancer | 142 |
| II. Pretherapeutic Immune Status in Early Lung Cancer | 142 |
| III. Prognostic Relevance of Pretherapeutic Immune Status | 143 |

| | |
|---|-----|
| IV. Possible Causes of Precancerous Immune Deficiencies | 144 |
| V. Tumor-Induced Immune Deficiency | 145 |
| VI. Chemotherapy and Immune Status | 146 |
| VII. Radiotherapy of Lung Cancer and Immune Response | 146 |
| VIII. How Patients Should Be Tested | 147 |
| IX. Conclusion | 149 |
| References | 149 |

Chapter 8 Nonspecific Causes of Death in Lung Cancer

A. *Philippe Chahinian*

| | |
|------------------------------|-----|
| I. Vascular Abnormalities | 151 |
| II. Infectious Complications | 153 |
| III. Conclusion | 156 |
| References | 156 |

Chapter 9 The Logical Basis of Radiation Treatment Policies in the Multidisciplinary Approach to Lung Cancer

Philip Rubin, Carlos A. Perez, and Bowen Keller

| | |
|---|-----|
| I. Defining the Target Group | 160 |
| II. Treatment Policies Based upon Anatomic-Histopathologic Classification | 165 |
| III. The Measurement of Response to Irradiation | 170 |
| IV. Best Technique of Radiation Therapy in Lung Cancer | 173 |
| V. New Strategies | 187 |
| VI. Appendix: Example of Calculation of Spinal Cord Dose | 190 |
| References | 193 |

Chapter 10 Problems of Best Supportive Therapy in Lung Cancer

Lucien Israel

| | |
|--|-----|
| I. Correcting Adrenal Insufficiency | 200 |
| II. Weight Loss, Immune Defense Mechanisms, Bone Marrow Functions, and Androgens | 200 |
| III. Specific Prophylaxis for Opportunistic Microbial Infections | 201 |
| V. Nonspecific Prophylaxis for Opportunistic Infections | 201 |
| VI. Prophylaxis for Pulmonary Embolism | 202 |
| VII. Conclusion | 202 |
| References | 203 |

Chapter 11 On Chemotherapy of Lung Cancer

Oleg S. Selawry

| | |
|---------------------|-----|
| I. Introduction | 205 |
| II. General Aspects | 206 |

| | |
|---|-----|
| III. Monochemotherapy | 212 |
| IV. Oligo- and Polychemotherapy | 219 |
| V. Regional Drug Administration | 225 |
| VI. Combination Chemotherapy | 228 |
| VII. Summary and Outlook | 235 |
| References | 236 |

Chapter 12 Palliative Surgery in Lung Cancer

Olivier Monod

| | |
|--|-----|
| I. Justification for Palliative Operations | 242 |
| II. Objections to Palliative Surgery | 251 |
| III. The Limits of Indications for Surgery | 251 |
| IV. General Strategy | 254 |
| References | 255 |

Chapter 13 The Role of Anticoagulation Chemotherapy in Lung Carcinoma

Elias G. Elias

| | |
|---|-----|
| I. Introduction | 259 |
| II. Heparin as Adjuvant to Chemotherapy— Pilot Study | 262 |
| III. Discussion | 266 |
| References | 270 |

Chapter 14 Nonspecific Immune Stimulation with Corynebacteria in Lung Cancer

Lucien Israel

| | |
|---|-----|
| I. A Brief Summary of the Experimental Properties of <i>Corynebacterium parvum</i> | 274 |
| II. Study Protocol | 274 |
| III. Results in Squamous Cell Carcinoma | 275 |
| IV. Results in Oat Cell Carcinoma | 276 |
| V. Results according to Pretherapeutic Immune Status | 276 |
| VI. Changes in Skin Tests during Treatment | 277 |
| VII. Leukopenia and Infection | 277 |
| VIII. Toxicity | 277 |
| IX. Discussion and Interpretation of Results | 278 |
| References | 279 |

Chapter 15 Presentation of the Current EORTC Lung Group Protocols for Immunostimulation with BCG in Lung Cancer

Lucien Israel

| | |
|---|-----|
| I. Adjuvant Postsurgical Protocol | 281 |
| II. Protocol for Local Unresectable Carcinoma | 282 |
| III. Discussion | 283 |

Chapter 16 Problems in Designing Postoperative
Strategies with Respect to Immune
Status, Kinetics, and Resistance

Lucien Israel

- I. Adjuvant Therapy and Immune Status 285
- II. Adjuvant Therapy and Kinetics 287
- III. Adjuvant Therapy, Resistance and Spread of
Disease 288
- IV. Hypotheses on Different Therapeutic Subgroups 290
- V. How Should Postsurgical Trials Be Designed? 291
- References 293

Chapter 17 A Discussion of Current Strategies for
Limited Unresectable Squamous Cell
Carcinoma and Adenocarcinoma of the Lung

Lucien Israel

- I. Is Radiotherapy a Safe and Useful Procedure? 295
- II. Concomitant Nonmyelotoxic Chemotherapy and
Radiotherapy 297
- III. Surgery in "Unresectable" Disease 298
- IV. Conclusion 298
- References 299

Chapter 18 A Discussion of Current Strategies for
Disseminated Lung Cancer

Lucien Israel

- I. Disseminated Disease, Immunity and Nonspecific
Immune Stimulation 302
- II. Disseminated Disease and Radiotherapy 302
- III. Disseminated Disease and Surgery 302
- IV. Disseminated Disease and Sequential
Chemotherapeutic Combinations 303
- V. Conclusion 304

| | |
|-----------------|-----|
| INDEX | 305 |
|-----------------|-----|

Chapter 1

Present Incidence of Lung Cancer: Epidemiologic Data and Etiologic Factors

A. Philippe Chahinian and Jacques Chrétien

| | |
|--------------------------------|----|
| I. Present Incidence | 2 |
| II. Epidemiologic Data | 3 |
| A. Age and Lung Cancer | 3 |
| B. Sex and Lung Cancer | 4 |
| C. Geographic Distribution | 4 |
| D. Occupation and Social Class | 4 |
| E. Ethnic Factors | 4 |
| III. Etiologic Factors | 5 |
| A. Tobacco | 5 |
| B. Air Pollution | 10 |
| C. Occupational Factors | 11 |
| D. Individual Factors | 15 |
| IV. Conclusions | 17 |
| References | 17 |

The history of lung cancer merges with that of its etiology. In 1420, shortly after the opening of the Schneeberg mines in Saxony (renowned today not only for their richness in various metals but also for radon) Theophrastus Paracelsus described the *Bergkrankheit* (or mountain sickness) in miners. It was only in 1879 that Harting and Hesse recognized the malignant nature of this disease, which they erroneously termed pulmonary sarcoma [89]. The accurate diagnosis of lung cancer was established in 1913 [15]. It is true that at that time the disease was extremely rare, since Adler was able to collect no more than 374 cases in the world medical literature [89]! Nevertheless, the role of cigarette smoking was already suspected.*

* For more details, the reader can refer to "Lung Cancer" by Selawry and Hansen [81a].

Since then, the incidence of lung cancer has increased incessantly, until today it has reached an alarming level. This dramatic and exceptional progression is one of the most striking facts in cancerology. Lung cancer causes more deaths among the male populations of all industrialized countries, than any other form of cancer, with almost 70,000 deaths in the United States alone in 1972 [87].

I. PRESENT INCIDENCE

Tables I and II show the annual mortality rate for lung cancer for each sex in most industrialized countries. For Doll, the morbidity rate may be assessed by multiplying the mortality rate by 1.20; this coefficient clearly shows the disastrous prognosis associated with the disease. Even more striking than the present-day absolute levels is the increase in incidence: lung cancer is on the rise in all countries, Great Britain being the record holder [21]. However, it is difficult to make statistical comparisons between countries in view of the disparity in age groups, information contained in death certificates, and accuracy of epidemiologic surveys [21]. In fact, all these factors contribute to an underestimation of the true incidence of the disease. The absolute incidence has nearly doubled every 10 years over the past few decades. This rise is a real one and cannot be attributed to improved diagnostic procedures, population increase, longer life span, or more accurate death registers [21, 48].

However, the most recent statistics reveal that this increase is slowing down in some male populations, namely, in the United States (in Caucasians), Great Britain, Finland, Denmark, and Japan [81]. In view of this finding, it may be hoped that the incidence of lung cancer is becoming

TABLE I
Primary Bronchogenic Carcinoma^{a, b}

| Year | France | | Great Britain | | Germany | | Italy | |
|------|--------|--------|---------------|--------|---------|--------|-------|--------|
| | Male | Female | Male | Female | Male | Female | Male | Female |
| 1955 | 20.6 | 5.5 | 69.3 | 10.6 | 34.4 | 6.0 | 15.6 | 4.1 |
| 1960 | 27.7 | 5.6 | 85.6 | 13.2 | 48.4 | 7.3 | 23.9 | 5.2 |
| 1965 | 35.0 | 6.4 | 95.7 | 17.0 | 56.9 | 9.0 | 34.0 | 6.2 |

^a From Council of Europe [21].

^b Mortality rate per 100,000 in four European countries.

TABLE II
Lung Cancer Death Rates per 100,000 Population in the United States^a

| Year | Male | Female |
|------|------|--------|
| 1958 | 31.9 | 5.5 |
| 1960 | 35.3 | 5.7 |
| 1965 | 43.0 | 7.7 |
| 1970 | 53.4 | 11.9 |

^a SOURCE: "Vital Statistics of the United States," U.S. Department of Health, Education and Welfare. Data kindly provided by Edwin Silverberg, American Cancer Society, New York.

stable or even decreasing [81], and this change should be appreciable after 1980 [53].

II. EPIDEMIOLOGIC DATA

A. Age and Lung Cancer

Generally speaking, the incidence of lung cancer in the male population is highest around the age of 65 and around the age of 75 in the female population. Beyond these ages, the incidence decreases. In fact, these data, derived from conventional mortality tables, are inaccurate since they are based on deaths of persons of different age groups studied at the same time [21]. Correct analysis can be made only through the study of cohort mortality tables, that is by following groups of people born in the same period. This method reveals that the decrease in incidence is illusory and that, in fact, the mortality rate continues to increase with age [21]. Furthermore, the most marked increase in mortality rate occurs in the oldest section of the population. This factor alone can account for the more advanced age at which maximum death rate is observed in the female population, since increase in mortality rate due to lung cancer is a more recent phenomenon among females than among males [21]. These findings suggest the involvement of some carcinogenic processes with a cumulative effect and a long latent period.

In contrast, lung cancer is rare before the age of 40, accounting for approximately 2% of all cases [1]. The absolute number of cases for this age group has remained stable in all countries, and the epidemiologic profile of the disease seems unremarkable [1]. For example, male predomi-

nance is still observed, but to a lesser degree. It even appears that the incidence is decreasing in this age group in the United States and in Great Britain [81], possibly as a result of environmental changes.

B. Sex and Lung Cancer

Male predominance is a constant feature of lung cancer, but the sex ratio (ratio of the number of male cases to the number of female cases) is presently changing. In the United States, the sex ratio reached its peak in 1960 (6.8 : 1) and has fallen consistently since to less than 5 : 1 in the Caucasian population [81]. This phenomenon is not due to a decrease in the male mortality rate but to a more rapid rise in the female mortality rate. This rise in female mortality became appreciable only after 1960 [13, 94]. Since then, the mortality rates for women have risen and are increasing at more than an exponential pace, as determined in the United States (in Caucasians), in Great Britain (peak sex ratio = 6.2 in 1960 as against 4.9 in 1969), and in Denmark [81]. A continued decrease in the sex ratio is likely over the next few decades because of an increasing incidence in the female population [13].

C. Geographical Distribution

Lung cancer is encountered predominantly in highly industrialized regions. The first striking increase in the incidence of the disease was reported immediately following World War I in the large industrial cities of Germany [89]. All other factors being equal, the death rate is usually 2 to 5 times greater in cities than in rural areas. Moreover, there is a correlation with the density of population and with the degree of urban concentration. Thus, the mortality rate due to lung cancer in conurbations is 20% higher than in small towns [21].

D. Occupation and Social Class

The poorest classes are the most severely affected. Mainly unskilled laborers are affected, with skilled workers affected to a lesser extent [21]. Analysis of this data is complex and is connected with the study of etiologic factors, such as smoking, occupational hazards, and environment.

E. Ethnic Factors

In the United States, the mortality rate due to lung cancer in both men and women is increasing approximately twice as fast for nonwhites as for whites [62]. This phenomenon emphasizes the important role of environ-

mental factors in the causation of the disease [49]. The importance of the environment is even more obvious in studies of migratory populations. In the United States, the mortality rate due to lung cancer has decreased for British and German immigrants, whereas it has increased for Italian and Scandinavian immigrants [48]. In Italian and Scandinavian immigrants the incidence of lung cancer has tended to approach that recorded in the United States. It would thus appear that variations between different ethnic groups might, in fact, be related to environmental factors and personal habits.

III. ETIOLOGIC FACTORS

The 60 to 90 m² of respiratory epithelium are an ideal target for atmospheric carcinogens carried by the 12 m³ of air daily inhaled by man. The large number of etiologic factors involved makes their study a complex one. Their analysis must take into account the interactions between numerous carcinogens, some of which have yet to be identified. These interactions may produce simple additive effects or synergistic effects. Furthermore, some factors are *initiators*, modifying the genetic apparatus and giving rise to a potential tumor cell. Others are *promoters*, inactive by themselves but able to stimulate the initiated cell, and thus contribute to tumor induction and proliferation [17, 18].

A. Tobacco

On this point, all epidemiologic investigations are in agreement [21]. In all countries, the increased incidence of lung cancer follows the increase in cigarette smoking. This strong relationship is based on the following evidence.

1. STATISTICAL EVIDENCE

The marked rise in the incidence of lung cancer coincided with a notable increase in cigarette consumption. In Finland, for example, annual cigarette production reached one million units a year as early as 1880, while in Norway production began only in 1886. In 1930 the incidence of lung cancer in Finland far exceeded that in Norway [51].

The following three statistical surveys were decisive.

a. The survey by Doll and Hill [25] involving 40,000 British doctors followed for 4 years. Of 36 cases of lung cancer, 25 involved smokers. The